Annexin A2/ANXA2 蛋白, Human

Annexin A2/ANXA2 Protein, Human is a 38kDa multifunctional protein which belongs to the annexin family. Annexin A2 is important for the regulation in the cellular growth and in signal transduction pathways. Annexin A2 also can be used as an autocrine factor that can heighten osteoclast formation and bone resorption^[1].

膜联蛋白由一个蛋白质家族组成，参与细胞膜动力学和膜相关蛋白调节的许多方面。
膜联蛋白 A2 是内皮细胞 (EC) 表面表达的膜联蛋白家族的重要成员。、巨噬细胞、单核细胞和各种类型的癌细胞。膜联蛋白 A2 对钙 (Ca²⁺) 和磷脂具有高亲和力结合。ANX A2 在许多生物过程中发挥着重要作用，例如胞吞作用、胞吐作用、自噬、细胞间通讯和纤溶酶原的生化激活。

Measured in a cell proliferation assay using A549 cells. The ED₅₀ this effect is ≤1.051 ng/mL, corresponding to a specific activity is ≥9.515×10⁵ units/mg.

• 
  Measured in a cell proliferation assay using A549 cells. The The ED₅₀ for this effect is 0.7184 ng/mL, corresponding to a specific activity is 1.39×10⁶ units/mg.

Human

E. coli

Tag Free

P07355-1 (S2-D339)

302  [NCBI]

STVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNILTNRSNAQRQDIAFAYQRRTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASMKGLGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLMVALAKGRRAEDGSVIDYELIDQDARDLYDAGVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDMLESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDMLKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD

Approximately 38 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized after extensive dialysis against 20 mM Histidine-HCl, 6% Sucrose, 4% Mannitol, 0.05% Tween 80, pH 5.5. or PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Mahesh C Sharma, et al. Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers. Int J Cancer. 2019 May 1;144(9):2074-2081.  [Content Brief]